Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Evercore ISI Group Maintains Outperform on Krystal Biotech, Raises Price Target to $206

Author: Benzinga Newsdesk | August 12, 2024 10:01am
Evercore ISI Group analyst Gavin Clark-Gartner maintains Krystal Biotech (NASDAQ:KRYS) with a Outperform and raises the price target from $201 to $206.

Posted In: KRYS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist